US 11,944,819 B2
Analyzing ECAP signals
Robert A. Corey, Arden Hills, MN (US); Kristin N. Hageman, Dayton, MN (US); David A. Dinsmoor, North Oaks, MN (US); Hank Bink, Golden Valley, MN (US); Christopher L. Pulliam, Plymouth, MN (US); and Thomas Adamski, Andover, MN (US)
Assigned to Medtronic, Inc., Minneapolis, MN (US)
Filed by Medtronic, Inc., Minneapolis, MN (US)
Filed on Jul. 9, 2020, as Appl. No. 16/924,990.
Prior Publication US 2022/0008726 A1, Jan. 13, 2022
Int. Cl. A61N 1/36 (2006.01); A61N 1/02 (2006.01); A61N 1/05 (2006.01); A61N 1/365 (2006.01); A61N 1/39 (2006.01)
CPC A61N 1/36139 (2013.01) [A61N 1/025 (2013.01); A61N 1/0534 (2013.01); A61N 1/365 (2013.01); A61N 1/3956 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A system comprising:
a stimulation generator configured to deliver a stimulation pulse to a patient;
sensing circuitry configured to sense an evoked compound action potential (ECAP) signal evoked from the stimulation pulse; and
processing circuitry configured to:
determine a maximum value of a derivative of the ECAP signal;
determine a minimum value of the derivative of the ECAP signal;
determine a difference between the maximum value of the derivative and the minimum value of the derivative, wherein the difference is a characteristic value of the ECAP signal; and
determine, using the characteristic value of the ECAP signal, at least one electrical stimulation parameter value defining an electrical stimulation therapy to be delivered to the patient.